Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02127502 · ClinicalTrials.gov registry record

VENUS: Septic Gene Expression Using SeptiCyte

A clinical trial of Sepsis and Systemic Inflammatory Response Syndrome (SIRS), sponsored by Immunexpress.

Completed
Registry status
379
Enrollment target
6
Study locations

NCT02127502 is a study of Sepsis and Systemic Inflammatory Response Syndrome (SIRS) that has completed, run by Immunexpress. The registered enrollment target is 379 participants, below the 6,560-participant average among 90 other Sepsis trials with a reported enrollment target (94% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02127502, a study of Sepsis and Systemic Inflammatory Response Syndrome (SIRS), has completed, sponsored by Immunexpress.

COMPLETED
Registry status
379 participants
Enrollment target
6
Study locations

Study Summary

The investigators seek to evaluate a new test for determining presence of infection/sepsis as compared to non-infection/systemic inflammatory response syndrome among critically ill patients within the first 24 hours of their being hospitalized in an intensive care unit (ICU) within the first 7 days of hospitalization. The primary purpose of the study is to validate SeptiCyte® Lab in this population as compared to: 1) the doctor's impression and 2) existing clinical parameters. The investigators also hope to assess how well a related, new blood test, SeptID® identifies different types of infection, as compared to cultures and other lab tests.

Conditions Studied

Sepsis Systemic Inflammatory Response Syndrome (SIRS)

Study Locations (6)

Illinois

  • Rush University Medical Center - Chicago
  • Loyola University Medical Center - Maywood

Georgia

  • Grady Memorial Hospital - Atlanta

Maryland

  • Johns Hopkins Hospital - Baltimore

New York

  • Northwell Health - New Hyde Park

Utah

  • Intermountain Medical Center - Murray

Trial Details

FieldValue
Enrollment Target 379 participants
Start Date 2014-04
Est. Completion 2016-12

Sponsor

Immunexpress

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02127502

The ClinicalTrials.gov registry entry for NCT02127502 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 379 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,560-participant average among 90 other Sepsis trials with a reported enrollment target (94% lower). The listed sponsor is Immunexpress, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 0 interventions.

NCT02127502 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Georgia, Maryland.

Frequently Asked Questions

What is clinical trial NCT02127502 about?

NCT02127502 is a clinical study titled "VENUS: Septic Gene Expression Using SeptiCyte". The investigators seek to evaluate a new test for determining presence of infection/sepsis as compared to non-infection/systemic inflammatory response syndrome among critically ill patients within the first 24 hours of their being hospitalized in an intensive care unit (ICU) within the first 7 days ...

What is the current status of trial NCT02127502?

This trial is currently completed. The enrollment target is 379 participants. The study started on 2014-04. Estimated completion is 2016-12.

What conditions does trial NCT02127502 study?

This clinical trial studies the following conditions: Sepsis, Systemic Inflammatory Response Syndrome (SIRS).

Who is sponsoring clinical trial NCT02127502?

This trial is sponsored by Immunexpress, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02127502 being conducted?

This trial has 6 study locations across Georgia, Illinois, Maryland, New York, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sepsis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sepsis

All registered trials for this condition

Systemic Inflammatory Response Syndrome (SIRS)

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.